Erratum: Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo (Int J Oncol (2011) 38 (973-983) DOI: 10.3892/ijo.2011.934);Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo

International Journal of Oncology

Volumn 38, Issue 4, 2011, Pages 973-983

  Gupta, Reshu ^a   Gogineni, Venkateswara Rao ^a   Nalla, Arun Kumar ^a   Chetty, Chandramu ^a   Klopfenstein, Jeffrey D ^a   Tsung, Andrew J ^a   Mohanam, Sanjeeva ^a   Rao, Jasti S ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Apoptosis; Caspase; Cathepsin B; p53; uPA; uPAR

Indexed keywords

BICISTRONIC SMALL INTERFERING RNA CONSTRUCT PU2; BICISTRONIC SMALL INTERFERING RNA CONSTRUCT PUC; CASPASE 3; CASPASE 9; CATHEPSIN B; CYTOCHROME C; DOUBLE STRANDED RNA; PLASMID VECTOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; PROTEINASE; SMALL INTERFERING RNA; SYNAPTOPHYSIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GENE THERAPY; CANCER RADIOTHERAPY; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LINE; CELL POPULATION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DNA VECTOR; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME RELEASE; GENE CONSTRUCT; GENE INACTIVATION; GENE REPRESSION; GENE SILENCING; GENE TRANSLOCATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; IONIZING RADIATION; MENINGIOMA; MITOCHONDRION; MOLECULARLY TARGETED THERAPY; MOUSE; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOSENSITIVITY; RECEPTOR DOWN REGULATION; RNA INTERFERENCE;

EID: 79952326174     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2021.5186     Document Type: Erratum

References (44)

1. Louis DN, Scheithauer BW, Budka H, von Deimling A and Kepes JJ: Meningiomas pathology and genetics of tumours of the nervous system. In: World Health Organization Classificat Pion of Tumours. Kleihues P and Cavenee WK(eds.) IARC Press, Lyon, pp176-184. 2000.
2. Barbaro NM, Gutin PH, Wilson CB, Sheline GE, Boldrey EB and Wara WM: Radiation therapy in the treatment of partially resected meningiomas. Neurosurgery 20: 525-528, 1987. (Pubitemid 17069668)
3. Goldsmith BJ, Wara WM, Wilson CB and Larson DA: Post-operative irradiation for subtotally resected meningiomas. A retrospective analysis of 140 patients treated from 1967 to 1990. J Neurosurg 80: 195-201, 1994.
4. Kokubo M, Shibamoto Y, Takahashi JA, Sasai K, Oya N, Hashimoto N and Hiraoka M: Efficacy of conventional radiotherapy for recurrent meningioma. J Neurooncol 48: 51-55, 2000.
5. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K and Tonn JC: Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol 44: 23-33, 1999. (Pubitemid 29515646)
6. Nakada M, Okada Y and Yamashita J: The role of matrix metalloproteinases in glioma invasion. Front Biosci 8: E261-E269, 2003.
7. Cheng JC, Chou CH, Kuo Ml and Hsieh CY: Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009-7018, 2006. (Pubitemid 44722069)
8. Speake WJ, Dean RA, Kumar A, Morris TM, Scholefield JH and Watson SA: Radiation induced MMP expression from rectal cancer is short lived but contributes to in vitro invasion. Eur J Surg Oncol 31: 869-874, 2005. (Pubitemid 41435256)
9. Kunigal S, Lakka SS, Joseph P, Estes N and Rao JS: Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-{kappa}B activity leading to apoptosis in breast tumors. Clin Cancer Res 14: 3617-3626, 2008.
10. Ossowski L, Clunie G, Masucci MT and Blasi F: In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115: 1107-1112, 1991.
11. Perry A, Jenkins RB, Dahl RJ, Moertel CA and Scheithauer BW: Cytogenetic analysis of aggressive meningiomas: possible diagnostic and prognostic implications. Cancer 77: 2567-2573, 1996. (Pubitemid 26169154)
12. Rempel SA, Schwechheimer K, Davis RL, Cavenee WK and Rosenblum Ml: Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 53: 2386-2392, 1993. (Pubitemid 23156829)
13. Gondi CS, Kandhukuri N, Dinh DH, Gujrati M and Rao JS: Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 31: 19-27, 2007.
14. Huang DC and Strasser A: BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103: 839-842, 2000.
15. Sionov RV and Haupt Y: The cellular response to p53: the decision between life and death. Oncogene 18: 6145-6157, 1999.
16. Ali IU, Schweitzer JB, Ikejiri B, Saxena A, Robertson JT and Oldfield EH: Heterogeneity of subcellular localization of p53 protein in human glioblastomas. Cancer Res 54: 1-5, 1994. (Pubitemid 24042075)
17. Eyfjord JE, Thorlacius S, Steinarsdottir M, Valgardsdottir R, Ogmundsdottir HM and Namthawat-Jonsson K: p53 abnormalities and genomic instability in primary human breast carcinomas. Cancer Res 55: 646-651, 1995.
18. Hoppe-Seyler F and Butz K: Tumor suppressor genes in molecular medicine. Clin Invest 72: 619-630, 1994. (Pubitemid 24277789)
19. Louis DN, von DA, Chung RY, Rubio MP, Whaley JM, Eibl RH, Ohgaki H, Wiestler OD, Thor AD and Seizinger BR: Comparative study of p53 gene and protein alterations in human astrocytic tumors. J Neuropathol Exp Neurol 52: 31-38, 1993. (Pubitemid 23016637)
20. Porter PL, Gown AM, Kramp SG and Coltrera MD: Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue. Am J Pathol 140: 145-153, 1992.
21. Starzynska T, Markiewski M, Domagala W, Marlicz K, Mietkiewski J, Roberts SA and Stern PL: The clinical significance of p53 accumulation in gastric carcinoma. Cancer 77: 2005-2012, 1996.
22. Prayson RA: Malignant meningioma: a clinicopathologic study of 23 patients including MIB1 and p53 immunohistochemistry. Am J Clin Pathol 105: 719-726, 1996.
23. Matsuno A, Nagashima T, Matsuura R, Tanaka H, Hirakawa M, Murakami M, Tamura A and Kirino T: Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas. Am J Clin Pathol 106: 776-781, 1996. (Pubitemid 27009496)
24. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
25. Vassalli JD, Sappino AP and Belin D: The plasminogen activator/plasmin system. J Clin Invest 88: 1067-1072, 1991.
26. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M and Rao JS: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23: 4681-4689, 2004. (Pubitemid 38859457)
27. INK4 and mitogen-activated protein kinase pathway. Cancer Res 67: 4956-4964, 2007.
28. Brockmann MA, Westphal M and Lamszus K: Improved method for the intracerebral engraftment of tumour cells and intra-tumoural treatment using a guide screw system in mice. Acta Neurochir (Wien) 145: 777-781, 2003. (Pubitemid 37204549)
29. Bostrom J, Meyer-Puttlitz B, Wolter M, Blaschke B, Weber RG, Lichter P, Ichimura K, Collins VP and Reifenberger G: Alterations of the tumor suppressor genes CDKN2A [p16(INK4a)], p14(ARF), CDKN2B [p15(INK4b)], and CDKN2C [p18(INK4c)]in atypical and anaplastic meningiomas. Am J Pathol 159: 661-669, 2001. (Pubitemid 32751096)
30. Simon M, Park TW, Koster G, Mahlberg R, Hackenbroch M, Bostrom J, Loning T and Schramm J: Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression. J Neurooncol 55: 149-158, 2001. (Pubitemid 34134038)
31. Modha A and Gutin PH: Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery 57: 538-550, 2005.
32. Kyritsis AP: Chemotherapy for meningiomas. J Neurooncol 29: 269-272, 1996.
33. Park HS, Yun Y, Kim CS, Yang KH, Jeong M, Ahn SK, Jin YW and Nam SY: A critical role for AKT activation in protecting cells from ionizing radiation-induced apoptosis and the regulation of acinus gene expression. Eur J Cell Biol 88: 563-575, 2009.
34. Gondi CS, Lakka SS, Dinh D, Olivero W, Gujrati M and Rao JS: Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth. Neuron Glia Biol 1: 165-176, 2004.
35. Sinha AA, Gleason DF, Deleon OF, Wilson MJ and Sloane BF: Localization of a biotinylated cathepsin B oligonucleotide probe in human prostate including invasive cells and invasive edges by in situ hybridization. Anat Rec 235: 233-240, 1993. (Pubitemid 23015297)
36. Murnane MJ, Sheahan K, Ozdemirli M and Shuja S: Stage-specific increases in cathepsin B messenger RNA content in human colorectal carcinoma. Cancer Res 51: 1137-1142, 1991.
37. Rempel SA, Rosenblum Ml, Mikkelsen T, Yan PS, Ellis KD, Golembieski WA, Sameni M, Rozhin J, Ziegler G and Sloane BF: Cathepsin B expression and localization in glioma progression and invasion. Cancer Res 54: 6027-6031, 1994. (Pubitemid 24378621)
38. Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson GL and Rao JS: Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis 13: 49-56, 1995.
39. Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C and Rassner G: Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer 91: 972-982, 2001.
40. Shetty S and Idell S: Urokinase induces expression of its own receptor in Beas2B lung epithelial cells. J Biol Chem 276: 24549-24556, 2001.
41. Haupt S, Berger M, Goldberg Z and Haupt Y: Apoptosis - the p53 network. J Cell Sci 116: 4077-4085, 2003. (Pubitemid 37337082)
42. Jaaskelainen J, Haltia M and Servo A: Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol 25: 233-242, 1986. (Pubitemid 16175898)
43. Mahmood A, Caccamo DV, Tomecek FJ and Malik GM: Atypical and malignant meningiomas: a clinicopathological review. Neurosurgery 33: 955-963, 1993. (Pubitemid 23358388)
44. Mahmood A, Qureshi NH and Malik GM: Intracranial meningiomas: analysis of recurrence after surgical treatment. Acta Neurochir (Wien) 126: 53-58, 1994. (Pubitemid 24068169)